Twice a Year, Zero New Infections: The HIV Prevention Breakthrough That Changes Everything

Picture taking a pill every single day for the rest of your life. Now picture taking an injection twice a year instead. That’s the shift happening right now in HIV prevention, and the results are so strong that researchers stopped the clinical trials early—not because something went wrong, but because continuing felt ethically wrong when one option was so clearly superior.

Two massive Phase 3 trials tested Lenacapavir, a subcutaneous injection given twice yearly, against the current gold standard: daily pills called Truvada or Descovy. The first trial, PURPOSE 1, involved 3,200 participants in Uganda and South Africa and showed 100% efficacy. Not a single new infection. The second trial, PURPOSE 2, expanded across continents and demographics—men, women, all ages—with 5,000 participants. The result: 99.9% reduction in infection rates. That’s not just good. That’s transformative.

Here’s why this matters beyond the numbers. The daily pills work, sure—they also achieved 99.9% protection during development. But adherence is brutal. Missing doses, skipping weeks, the mental and physical toll of remembering a medication every single day for years? That’s where real life crashes into clinical theory. Twice-yearly injections eliminate that friction entirely. And there’s something else: in countries like Uganda where male homosexuality is illegal, taking a visible daily pill can signal sexual orientation and invite legal or social danger. A twice-yearly doctor’s visit carries no such stigma.

Lenacapavir, developed by Gilead Sciences, works by targeting a protein on the HIV capsid shell that remains constant no matter how the virus mutates. It disrupts the capsid’s ability to complete its lifecycle, stopping infection before it starts. The drug earned Science Magazine’s Breakthrough of the Year in 2024 and was approved by the FDA under the brand name Yeztugo. The development cost Gilead over a billion dollars—but they’re committing to provide it at cost in low-income regions and have licensed generic manufacturers to produce it for roughly $40 per year in 120 low and middle-income countries starting in 2027.

That price point matters as much as the efficacy. Prevention that only reaches wealthy nations isn’t prevention—it’s privilege. The global HIV burden falls hardest on sub-Saharan Africa, Southeast Asia, and other regions where cost is a real barrier. By making Lenacapavir affordable at scale, Gilead has opened a door that could reshape the HIV epidemic. We’re not talking about managing the disease anymore. We’re talking about preventing it almost entirely.